Table 2. Comparison of patients with and without complete mucosal healing.
| CMH (+) (n = 15) | CMH (−) (n = 35) | P-value | |
|---|---|---|---|
| Age (mean, SD) | 48.13 (15.17) | 45.71 (12.51) | 0.560 |
| WBC count (median, IQR) | 5.7 (5.4–8.6) | 6.7 (5.4–8.2) | 0.8489 |
| Hb (median, IQR) | 16.7 (13.8–15.3) | 17 (11.4–14.7) | 0.0284 |
| Platelet (median, IQR) | 233 (192–265) | 287 (220–350)) | 0.0466 |
| iFOBT, ng/mL (median, IQR) | 7 (7–22.5) | 121 (8.5–400) | 0.0003 |
| FC, µg/g (median, IQR) | 59.95 (12.88–110.5) | 555 (79.96–1687.34) | 0.0028 |
| Disease distribution (E1/E2/E3) | 3∕7∕5 | 10∕13∕12 | 0.7643 |
| Mayo score stool frequency (0/1/2/3) | 4∕9∕2∕0 | 7∕13∕10∕5 | 0.0694 |
| Mayo score rectal bleeding (0/1/2/3) | 12∕3∕0∕0 | 17∕8∕8∕2 | 0.0162 |
| Physician rating of disease activity (0/1/2/3) | 9∕6∕0∕0 | 7∕20∕7∕1 | 0.0032 |
| Current medication | |||
| –steroids (%) | 20% | 40% | 0.1756 |
| –oral 5-ASA (%) | 93.3% | 94.3% | 0.8976 |
| –rectal 5-ASA (%) | 60% | 51.4% | 0.5812 |
| –immune modulator (%) | 20% | 25.7% | 0.6678 |
| − biologic agent (%) | 6.7% | 0% | 0.1266 |
Notes.
- 5-ASA
- 5-aminosalicylic acid
- BMI
- body mass index
- CMH
- complete mucosal healing
- Hb
- hemoglobin
- iFOBT
- immune fecal occult blood test
- WBC
- white blood cell